At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
RZL-012drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Phase 2a Clinical Trial for the Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease
In Brief
A Phase 2 clinical trial evaluating RZL-012 for Lipedema and Dercum Disease. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee and men with Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLipedema, Dercum Disease
CountriesUnited States
CollaboratorsUniversity of Arizona
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJun 2018
Primary CompletionMay 2019
TodayJul 2026
First PostedApr 10, 2018
Enrollment StartJun 28, 2018
Primary CompletionMay 2, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.2 years ago
Interventions
RZL-012drug
The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites